SIN3B_role_in_melanoma_resistance_and_progression
Cutaneous melanoma accounts for the majority of skin cancer deaths, owing to its aggressiveness and resistance to targeted therapies, primarily due to the presence of phenotypic and genetic heterogeneity. Thus, there is a dire need to identify new biomarkers of therapy resistance in melanoma, which can aid the development of new therapeutic strategies. SIN3B scaffolding protein has been shown to have an implication in cancer progression. However, the mechanisms underlying SIN3B role in melanoma is currently unknown. Therefore, this study aims to characterize SIN3B molecular function and regulation during melanoma progression and therapy resistance.